title: Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research.
abstract: Dexmedetomidine is currently used in the US in the treatment of alcohol withdrawal syndrome (AWS) in the intensive care unit (ICU) setting, although data to support this practice are limited. Dexmedetomidine targets the noradrenergic system, an important but frequently overlooked secondary mechanism in the development of AWS, and, in doing so, may reduce the need for excessive benzodiazepine use which can increase the risk of γ-aminobutyric acid (GABA)-mediated deliriogenesis and respiratory depression. The purpose of this narrative review is to evaluate available literature reporting on the safety and efficacy of dexmedetomidine for AWS in the ICU setting. An English-language MEDLINE search (1966 to July 2013) was performed to identify articles evaluating the efficacy and safety of dexmedetomidine for AWS. Case series, case reports and controlled trials were evaluated for topic relevance and clinical applicability. Reference lists of articles retrieved through this search were reviewed to identify any relevant publications. Studies focusing on the safety and efficacy of dexmedetomidine for AWS in humans were selected. Studies were included if they were published as full articles; abstracts alone were not included in this review. Eight published case studies and case series were identified. Based on a limited body of evidence, dexmedetomidine shows promise as a potentially safe and possibly effective adjuvant treatment for AWS in the ICU. Prospective, well-controlled studies are needed to confirm the safety and efficacy of the use of dexmedetomidine in AWS.
authors: Department of Pharmacy Practice, Campbell University School of Pharmacy and Health Sciences, P.O. Box 3089, Buies Creek, NC, 27710, USA, Andrew.Muzyk@duke.edu.
authors: Andrew J
authors: AJ
authors: Muzyk
authors: Suzanne
authors: S
authors: Kerns
authors: Scott
authors: S
authors: Brudney
authors: Jane P
authors: JP
authors: Gagliardi
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D035843:Biomedical Research; D003422:Critical Care / Q000379:methods; D020927:Dexmedetomidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000431:Ethanol / Q000009:adverse effects*; D006801:Humans; D007362:Intensive Care Units; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000431:Ethanol; D020927:Dexmedetomidine
references: Alcohol. 2008 Mar;42(2):91-7
references: 18358987
references: J Anesth. 2012 Aug;26(4):601-5
references: 22584816
references: J Crit Care. 2009 Dec;24(4):568-74
references: 19682844
references: Intensive Care Med. 2009 Feb;35(2):282-90
references: 18795253
references: Alcohol Alcohol. 2003 May-Jun;38(3):224-31
references: 12711656
references: Cochrane Database Syst Rev. 2011 Jun 15;(6):CD008537
references: 21678378
references: Am J Health Syst Pharm. 2007 Jan 1;64(1):37-44
references: 17189578
references: Ann Pharmacother. 2008 Nov;42(11):1703-5
references: 18780809
references: Ann Pharmacother. 2011 May;45(5):649-57
references: 21521867
references: JAMA. 1997 Jul 9;278(2):144-51
references: 9214531
references: Alcohol Clin Exp Res. 1994 Dec;18(6):1312-6
references: 7695023
references: Ann Pharmacother. 2009 Dec;43(12):2064-74
references: 19934395
references: Alcohol. 1997 Nov-Dec;14(6):537-44
references: 9401667
references: Arch Intern Med. 2004 Jul 12;164(13):1405-12
references: 15249349
references: Am Fam Physician. 2004 Mar 15;69(6):1443-50
references: 15053409
references: Anesthesiology. 2003 Feb;98(2):575-7
references: 12552220
references: Eur J Intern Med. 2009 Nov;20(7):690-4
references: 19818288
references: Ann Intern Med. 1987 Dec;107(6):875-89
references: 2825572
references: J Anesth. 2013 Feb;27(1):135-6
references: 23011118
references: South Med J. 2012 Nov;105(11):607-12
references: 23128805
references: Alcohol. 1995 Sep-Oct;12(5):439-46
references: 8519439
references: Ann Intensive Care. 2012 May 23;2(1):12
references: 22620986
references: Chest. 2010 Oct;138(4):994-1003
references: 20923804
references: Pharmacotherapy. 2013 Feb;33(2):165-86
references: 23386596
references: Alcohol Clin Exp Res. 1997 Aug;21(5):804-8
references: 9267529
references: Neurocrit Care. 2010 Jun;12(3):356-61
references: 20217277
references: Science. 1981 Sep 4;213(4512):1135-7
references: 7268421
references: Laryngoscope. 2012 Aug;122(8):1739-47
references: 22566069
references: J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):854-62
references: 17986499
references: Drugs. 2011 Jul 30;71(11):1481-501
references: 21812509
references: Gen Hosp Psychiatry. 2006 Jul-Aug;28(4):362-3
references: 16814639
references: Intensive Care Med. 2013 Jan;39(1):16-30
references: 23184039
references: Crit Care. 2009;13(3):R75
references: 19454032
references: J Stud Alcohol. 1996 Sep;57(5):471-4
references: 8858544
references: Intensive Care Med. 2004 Dec;30(12):2188-96
references: 15338124
references: Lancet. 1997 Jun 28;349(9069):1897-900
references: 9217770
references: J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):E45-6
references: 23037682
references: Alcohol Health Res World. 1998;22(1):38-43
references: 15706731
references: Anaesthesia. 2006 Mar;61(3):299-300
references: 16480364
references: Alcohol Clin Exp Res. 1999 Mar;23(3):432-8
references: 10195815
references: Neurocrit Care. 2011 Aug;15(1):175-81
references: 20198514
references: Eur J Emerg Med. 2013 Dec;20(6):425-7
references: 23247391